A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials
2014
Neuron
As the field begins to test the concept of preclinical neurodegenerative disease, the hypothetical stage of disease when the pathophysiological process has begun in the brain but clinical symptoms are not yet manifest, a number of intriguing questions have already arisen. In particular, in preclinical Alzheimer's disease (AD), the temporal relationship of amyloid markers to markers of neurodegeneration and their relative utility in the prediction of cognitive decline among clinically normal
doi:10.1016/j.neuron.2014.10.038
pmid:25442939
pmcid:PMC4285623
fatcat:qyzgd7sbirfl7ml7hokqs33h5a